ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a collaboration agreement to help develop and manufacture biologics and small molecule drug candidates for ALSA’s portfolio of pre-clinical and early clinical biotechs.   The biopharmaceutical industry is experiencing a global shift towards new molecular formats and more complex molecules, including bi- and multi...